Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:

• Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
• Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
• Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
• Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
• Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
• Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
• Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
• Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
• Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
• Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

• Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
• Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
• Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
• Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

• Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
• Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
• Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
• Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

• Introduction (0:00)
• New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
• Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)
• Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

• Introduction (0:00)
• Minimal Residual Disease Assays in Community-Based Practice (1:24)
• New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
• Richter Transformation (30:43)
• Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)

CME information and select publications

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

• Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
• Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
• Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
• Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
• Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
• Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Treatment (1:33)
• Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Therapy (2:48)
• Relapsed/Refractory Disease (39:30)

CME information and select publications